20:46 , Dec 21, 2018 |  BC Week In Review  |  Company News

FDA picks Flatiron's Abernethy for No. 2 spot

FDA has hired data scientist and oncologist Amy Abernethy of Flatiron Health Inc. for its No. 2 spot, succeeding Rachel Sherman, who is retiring. FDA Commissioner Scott Gottlieb told BioCentury he expects Abernethy to evaluate...
18:30 , Nov 30, 2018 |  BC Week In Review  |  Financial News

CareDx closes $56M follow-on

Molecular diagnostics company CareDx Inc. (NASDAQ:CDNA) raised $56.4 million through the sale of 2.3 million shares at $24.50 in a follow-on underwritten by Jefferies, Piper Jaffray and Craig-Hallum. The figures include the sale of a...
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
21:46 , Nov 9, 2018 |  BioCentury  |  Finance

Doubling down on debt

Increased demand for debt financings led Perceptive Advisors to double the capital for its second debt fund: Perceptive Credit Opportunities Fund II. Perceptive closed Fund II at $675 million, just two years after closing its...
17:27 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed on Nov. 5 its second debt fund, Perceptive Credit Opportunities Fund II, at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which...
22:07 , Nov 5, 2018 |  BC Extra  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed its second debt fund Perceptive Credit Opportunities Fund II at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which closed at $323...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
18:14 , May 11, 2018 |  BC Week In Review  |  Company News

CareDx licenses Illumina's transplant diagnostics

CareDx Inc. (NASDAQ:CDNA) received exclusive, worldwide rights to next-generation sequencing bone marrow and solid organ transplantation diagnostics from Illumina Inc. (NASDAQ:ILMN). Illumina received $5 million up front and is eligible for mid-single to low-double digit...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
19:48 , Oct 13, 2017 |  BC Week In Review  |  Financial News

CareDx raises $20M follow-on

Molecular diagnostics company CareDx Inc. (NASDAQ:CDNA) raised $20 million through the sale of 5 million shares at $4 in a bumped-up follow-on underwritten by Craig-Hallum Capital Group and H.C. Wainwright. The figures include the sale...